DrugPatentWatch Database Preview
PROVAYBLUE Drug Profile
» See Plans and Pricing
When do Provayblue patents expire, and what generic alternatives are available?
Provayblue is a drug marketed by Provepharm Sas and is included in one NDA.
The generic ingredient in PROVAYBLUE is methylene blue. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylene blue profile page.
Summary for PROVAYBLUE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 99 |
Clinical Trials: | 1 |
Patent Applications: | 3,988 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for PROVAYBLUE |
DailyMed Link: | PROVAYBLUE at DailyMed |


Generic Entry Opportunity Date for PROVAYBLUE
Generic Entry Date for PROVAYBLUE*:
Constraining patent/regulatory exclusivity:
FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA. NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PROVAYBLUE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Provepharm Life Solutions | Phase 2 |
Carilion Clinic | Phase 2 |
Pharmacology for PROVAYBLUE
Drug Class | Oxidation-Reduction Agent |
Mechanism of Action | Oxidation-Reduction Activity |
US Patents and Regulatory Information for PROVAYBLUE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Provepharm Sas | PROVAYBLUE | methylene blue | SOLUTION;INTRAVENOUS | 204630-002 | Jul 18, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
Provepharm Sas | PROVAYBLUE | methylene blue | SOLUTION;INTRAVENOUS | 204630-001 | Apr 8, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |